One Simple Move

ONE SIMPLE MOVE NOW—make the move to ONE-dose convenience for 24-hour, continuous dopamine stimulation.

Noncompliance With PD Medications Is High CASE PROFILE—GLEN, WANTS A SIMPLER PD MEDICATION

•

55 years of age

•

Hoehn and Yahr stage II (diagnosed 2 years ago)

•

Very active, works full time

•

eceiving 9 mg immediateR release ropinirole and L-dopa

•

Has admitted to skipping or forgetting to take his afternoon dose

Once-Daily REQUIP XL 24-hour Extended-Release Formulation for Continuous Dopamine Stimulation

Unique 3-layer tablet extends the rate, location, and timing of ropinirole release, allowing for convenient once-daily dosing

Plasma Concentration Over Time: REQUIP XL 24-hour and IR Ropinirole CONVERT FROM IR ROPINIROLE TO REQUIP XL 24-HOUR

0.7

A Third of Patients Are Noncompliant in the First Year of Treatment Rate of Nonadherence With PD Medications by Duration of Follow-Up

Rate of nonadherence

57%

REQUIP plasma concentration (ng/mL)

TREATMENT STRATEGY

0.6 0.5 0.4 0.3 0.2 IR ropinirole REQUIP XL 24-hour

0.1 0

50%

0

4

8

12

16

20

Time after dosing (hours)

43%

• Avoids peaks and troughs associated with immediate-release DAs • Achieves steady-state concentrations of ropinirole within 4 days of dosing

32%

Dosing Simplicity Leads to Compliance 12 Months

24 Months

36 Months

48 Months

Retrospective analysis of prescription drug utilization by a US managed care population (N=3119) of patients with a PD diagnosis and treatment with a PD medication.

REQUIP XL 24-hour provides a new level of convenience with once-daily dosing and simple titration

Long titration and dosing multiple times per day are strong factors for noncompliance with PD medications • Noncompliance may lead to suboptimal efficacy, premature treatment modifications, increased symptoms, and poor outcomes

Treatment strategies that simplify PD dosing–shorter titrations, reducing the number of doses per day, lower pill burdens–may improve adherence and result in better symptom control

AN INSTANT CONVERSION

4

Convert patients overnight from REQUIP IR to REQUIP XL 24-hour

A SIMPLE START

The 4-week Sample Kit provides a convenient, easy way to get patients started on REQUIP XL 24-hour

24

ONCE DAILY

Co n ion n ym veni rat osi t i e t d pt ple om nt once ily -daily dosing • Sim e-da atic ve nc treat ni en ment • Convenient o to nc e -d aily dosi ng • S imple titration

im

HOUR

•S

trat ion

ler to

24

g

ple ti

nd ty a safe Proven

One Dose Makes the Day n ve Pro

es

ab • With NEW REQUIP XL 24-hour, ilit nt e yp m tiv the first and only once-daily rofi eat ffec r le • t tic Effecti Pro •E dopamine agonist for Parkinson’s ve symptoma sa ven file o r fe s p a on fety and tolerability disease, patients can take their dose ty •C an t dt and get on with their day. en ole atm rab e r t ility atic profil e • Effective symptom • The only once-a-day oral DA • Simple titration • Significant reduction in “off” time within 2 weeks • Proven safety and tolerability

In the treatment of Parkinson’s disease…

Monotherapy for Patients With Early Parkinson’s Disease

Compliance Leads to Control

NEW Once-Daily REQUIP XL 24-hour Controls PD Signs and Symptoms as Effectively as Immediate-Release Ropinirole

CASE PROFILE—GLEN, CONCERNED ABOUT PILL BURDEN

Adjusted Mean Change From Baseline in UPDRS Total Motor Score (Part III) Prior to Formulation Switch at Week 20 (LOCF)

• 65 years of age; Hoehn and Yahr stage I • Newly diagnosed (no previous therapy) • Recently retired; physically active

REQUIP XL 24-hour

• Currently takes once-daily hypertension Adjusted Mean Change From Period Baseline

and cholesterol medications • Prefers simplicity of once-daily

medications; concerned about dosing multiple times a day

TREATMENT STRATEGY

IR Ropinirole

0

STARTED ON ONCE-DAILY REQUIP XL 24-HOUR USING THE 4-WEEK SAMPLE KIT

P=0.0582

-2 -4 -6 -8 -10

-10.6

-8.8

-12

• Doses of REQUIP XL 24-hour could be increased more quickly

than IR doses, resulting in an earlier response on UPDRS motor and CGI-I scores Dosing multiple times per day and long dosing titration may lead to noncompliance with PD medications

1 in 3

PD patients noncompliant at 1 year

• In a study of PD patients, the rate of noncompliance with

PD medications was high—and increased over time* —32% at 12 months

—43% at 24 months

—50% at 36 months

—57% at 48 months

* Retrospective analysis of prescription drug utilization by a US managed care population (N=3119) of patients with a PD diagnosis and treatment with a PD medication.

Treatment strategies that simplify PD dosing­—shorter titrations, reducing the number of doses per day, lower pill burdens—may improve compliance and result in better symptom control

Patients were able to start on a higher dose and titrate faster with REQUIP XL 24-hour than with IR ropinirole—without added side effects

Dosing Simplicity Leads to Compliance REQUIP XL 24-hour provides a new level of convenience with once-daily dosing and simple titration

AN INSTANT CONVERSION

4

Convert patients overnight from REQUIP IR to REQUIP XL 24-hour

A SIMPLE START

The 4-week Sample Kit provides a convenient, easy way to get patients started on REQUIP XL 24-hour